Human Chronic Lymphoid Leukemia Bone Marrow CD19+/CD5+ B Cells (Newly Diagnosed/Untreated)

Description

Human Chronic Lymphoid Leukemia (CLL) Bone Marrow CD19+/CD5+ B Cells (Newly Diagnosed/Untreated) are freshly isolated from the bone marrow aspirates of newly diagnosed, untreated CLL patients. These cells represent a malignant B cell population, characterized by the aberrant co-expression of CD19 and CD5 surface markers—an immunophenotypic hallmark of CLL and critical for identifying CLL diagnosis biomarkers. Morphologically, CLL B cells are small, mature-appearing lymphocytes with scant cytoplasm and condensed chromatin. Cytogenetic analysis confirms clonal chromosomal abnormalities commonly associated with CLL, such as del(13q) or trisomy 12. The cells are cryopreserved post-isolation to preserve their native phenotype and functional integrity. CLL CD19+/CD5+ B cells are non-proliferative in vitro and should not be repeatedly thawed or passaged. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.